What are the main alternatives to Cosentyx for plaque psoriasis?
Cosentyx (secukinumab) is an IL‑17A inhibitor used for several inflammatory conditions, including plaque psoriasis. Alternatives in the same treatment area include other biologics that target related immune pathways:
- IL‑17 pathway options such as ixekizumab (Taltz) and brodalumab (Siliq/Tremfya is not IL‑17; see below).
- IL‑23 inhibitors (often used when IL‑17 is not ideal), such as ustekinumab is older and not IL‑23, while newer IL‑23 agents include guselkumab, risankizumab, and tildrakizumab.
- TNF‑alpha inhibitors, including etanercept, adalimumab, and infliximab (commonly used options before IL‑17/IL‑23 became widespread).
- JAK inhibitors are another non-biologic option in some jurisdictions and patient profiles, though the suitability depends on the specific diagnosis and risk factors.
Because Cosentyx is a prescription-only biologic, the “best alternative” depends on diagnosis (psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis), severity, prior treatment history, and comorbidities.
If you mean psoriatic arthritis or ankylosing spondylitis, what are the Cosentyx alternatives?
For inflammatory arthritis indications, alternatives typically come from the same major drug classes:
- Other IL‑17 pathway drugs (often the closest functional alternatives when IL‑17 is the chosen mechanism).
- IL‑23 inhibitors (more commonly used for psoriasis; arthritis data/fit varies by product and guideline).
- TNF inhibitors, which are established for psoriatic arthritis and ankylosing spondylitis.
- Conventional and targeted non-biologics may be considered in some cases, but the exact fit depends on how severe the disease is and which joints are involved.
What’s the difference between IL‑17 and IL‑23 inhibitors vs TNF inhibitors (why switch)?
Patients and clinicians often switch away from Cosentyx for reasons like inadequate response, loss of response, side effects, access/cost, or preference for a different dosing schedule. Mechanistically:
- IL‑17 inhibitors aim to block IL‑17A signaling, which is strongly linked to skin inflammation and some arthritis pathways.
- IL‑23 inhibitors target upstream immune signaling that drives inflammatory pathways in psoriasis and, in many patients, can offer durable control.
- TNF inhibitors target a broader inflammatory cytokine pathway and are often used when IL‑17/IL‑23 options are unsuitable.
Are there biosimilars that count as alternatives to Cosentyx?
Cosentyx is a biologic, but whether a “biosimilar to Cosentyx” exists depends on regulatory approvals in the relevant country and the specific active ingredient (secukinumab). If a biosimilar is approved where you live, it can be a direct cost/performance alternative.
For current competitive landscape and patent/exclusivity details, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ (search for “secukinumab” or “Cosentyx” there).
What should patients ask their doctor before choosing a Cosentyx alternative?
Key practical questions include:
- Which indication you’re treating (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or another approved use).
- What you tried before and whether you had primary non-response or loss of response.
- Safety history (for example, infection history and other risk factors).
- Whether you need something that covers both skin and joint symptoms.
- Dosing convenience and insurance coverage, since these often drive the final choice.
How do pricing and access compare between Cosentyx and alternatives?
Pricing varies widely by country, insurance plan, and whether a manufacturer discount, prior authorization, or a biosimilar is available. If cost is a major driver, it’s reasonable to ask your insurer or clinic whether:
- There’s coverage for another biologic in the same class (IL‑17 or IL‑23).
- A biosimilar is available for the closest alternative drug.
- Switching is likely to require a new prior authorization based on your prior treatment response.
If you tell me your exact diagnosis (psoriasis vs psoriatic arthritis vs ankylosing spondylitis), your prior meds, and your country, I can narrow the list of the most relevant Cosentyx alternatives.
Sources
- DrugPatentWatch.com (secukinumab/Cosentyx patent & competition research)